Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FBQAF
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,055
Award facts
- Contract value 100% obligated
- $11,054.58 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has awarded a delivery order valued at $11,054.58 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, issued on January 27, 2026, represents performance through February 18, 2026, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products supporting Department of Defense healthcare operations globally.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with demonstrated performance across a diverse portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The contractor's appointment under the PPV-G GEN V prime vendor contract, which features a ceiling value of $499,999,999 and extends through December 31, 2036, positions the company to fulfill recurring medical supply needs of military healthcare facilities worldwide. Xolair, a biologic immunosuppressant agent, represents one of the specialized pharmaceutical products within the company's established supply capabilities to the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FBQAF?
SPE2DR26FBQAF was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FBQAF worth?
The government has obligated $11,055 on SPE2DR26FBQAF.
Is contract SPE2DR26FBQAF an order under another contract?
Yes. SPE2DR26FBQAF is a delivery order under SPE2DR25D9304, an indefinite delivery contract.
Was contract SPE2DR26FBQAF competed?
The extent of competition for SPE2DR26FBQAF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award